Vibration-controlled transient elastography for significant fibrosis in treatment- naïve chronic hepatitis B patients: A systematic review and meta-analysis
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Backgrounds/Aims: Accurate diagnosis of significant liver fibrosis in patients with chronic hepatitis B (CHB) is crucial when determining whether to initiate antiviral treatment (AVT). We conduct a meta-analysis to assess the diagnostic performance of vibration-controlled transient elastography (VCTE) for significant liver fibrosis in AVT-naïve CHB patients with serum alanine transaminase (ALT) levels within 5-fold the upper limit of normal (ULN). Methods: The Ovid-Medline, EMBASE, Cochrane, and KoreaMed databases were searched to identify studies that compared the performance of VCTE and liver biopsy (reference standard) when diagnosing significant liver fibrosis (≥F2) in AVT-naïve CHB patients with ALT within 5-fold the ULN. A hierarchical summary receiver operating characteristic curve (HSROC) and bivariate model were performed to evaluate the diagnostic performance of VCTE in the meta-analysis. Results: Eight studies (2,003 patients) were included. The summary sensitivity and specificity for diagnosis of significant liver fibrosis were 0.78 (95% confidence interval [CI], 0.66–0.86) and 0.72 (95% CI, 0.60–0.82), respectively. The HSROC for the diagnosis of significant liver fibrosis was 0.81 (95% CI, 0.72–0.86). The optimal cutoff value of VCTE for diagnosis of significant liver fibrosis was 7.7 kPa with a sensitivity of 0.64 (95% CI, 0.50–0.76) and specificity of 0.83 (95% CI, 0.72–0.90). Conclusions: Our study demonstrated that VCTE has an acceptable diagnostic performance for significant liver fibrosis in AVT-naïve CHB patients with ALT within 5-fold the ULN.
Abstract
Backgrounds/Aims: Accurate diagnosis of significant liver fibrosis in patients with chronic hepatitis B (CHB) is crucial when determining whether to initiate antiviral treatment (AVT). We conduct a meta-analysis to assess the diagnostic performance of vibration-controlled transient elastography (VCTE) for significant liver fibrosis in AVT-naïve CHB patients with serum alanine transaminase (ALT) levels within 5-fold the upper limit of normal (ULN). Methods: The Ovid-Medline, EMBASE, Cochrane, and KoreaMed databases were searched to identify studies that compared the performance of VCTE and liver biopsy (reference standard) when diagnosing significant liver fibrosis (≥F2) in AVT-naïve CHB patients with ALT within 5-fold the ULN. A hierarchical summary receiver operating characteristic curve (HSROC) and bivariate model were performed to evaluate the diagnostic performance of VCTE in the meta-analysis. Results: Eight studies (2,003 patients) were included. The summary sensitivity and specificity for diagnosis of significant liver fibrosis were 0.78 (95% confidence interval [CI], 0.66–0.86) and 0.72 (95% CI, 0.60–0.82), respectively. The HSROC for the diagnosis of significant liver fibrosis was 0.81 (95% CI, 0.72–0.86). The optimal cutoff value of VCTE for diagnosis of significant liver fibrosis was 7.7 kPa with a sensitivity of 0.64 (95% CI, 0.50–0.76) and specificity of 0.83 (95% CI, 0.72–0.90). Conclusions: Our study demonstrated that VCTE has an acceptable diagnostic performance for significant liver fibrosis in AVT-naïve CHB patients with ALT within 5-fold the ULN.
참고문헌 (50)
- Lin CL, "Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection", Clin Mol Hepatol, 29, pp.605~622 (2023)
- Wang T, "Hepatitis B virus(HBV)viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate(TDF)vs. untreated : a retrospective longitudinal UK cohort study", BMC Infect Dis, 21, pp.610~ (2021)
- Lee SK, "HBeAg-positive grey-zone patients : Treatment beyond guideline recommendations?", Clin Mol Hepatol, 29, pp.825~827 (2023)
- Yoo JJ, "Longterm prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase", Clin Mol Hepatol, 29, pp.482~495 (2023)
- Tapper EB, "Use of liver imaging and biopsy in clinical practice", N Engl J Med, 377, pp.756~768 (2017)
- Oh JH, "Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?", Clin Mol Hepatol, 29, pp.367~370 (2023)
- Udompap P, "Prospective comparison of transient elastography, point shear wave elastography, APRI and FIB-4for staging liver fibrosis in chronic viral hepatitis", J Viral Hepat, 27, pp.437~448 (2020)
- Reinson T, "Noninvasive serum biomarkers for liver fibrosis in NAFLD : current and future", Clin Mol Hepatol, 29(Suppl), pp.S157~S170 (2023)
- Yu JH, "Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease : current and future", Clin Mol Hepatol, 29(Suppl), pp.S136~S149 (2023)
- Mingkai L, "Diagnostic performance of elastography on liver fibrosis in antiviral treatment-naive chronic hepatitis B patients: a meta-analysis", Gastroenterol Rep (Oxf), 10, pp.goac005~ (2022)
- Qi X, "Transient elastography for significant liver fibrosis and cirrhosis in chronic hepatitis B : A meta-analysis", Can J Gastroenterol Hepatol, 2018, pp.3406789~ (2018)
- Li Y, "Systematic review with meta-analysis : the diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B", Aliment Pharmacol Ther, 43, pp.458~469 (2016)
- Chon YE, "Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B : a meta-analysis", PLoS One, 7, pp.e44930~ (2012)
- Korean Association for the Study of the Liver(KASL), "KASL clinical practice guidelines for management of chronic hepatitis B", Clin Mol Hepatol, 25, pp.93~159 (2019)
- Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance", Clin Liver Dis(Hoboken), 12, pp.33~34 (2018)
- European Association for the Study of the Liver, "EASL 2017Clinical Practice Guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
- Sarin SK, "Asian-Pacific clinical practice guidelines on the management of hepatitis B : a 2015 update", Hepatol Int, 10, pp.1~98 (2016)
- Sagir A, "Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage", Hepatology, 47, pp.592~595 (2008)
- Arena U, "Acute viral hepatitis increases liver stiffness values measured by transient elastography", Hepatology, 47, pp.380~384 (2008)
- Higgins JPT, "Cochrane Handbook for Systematic Reviews of Interventions" (2019), Wiley-Blackwell
- Page MJ, "The PRISMA 2020 statement : an updated guideline for reporting systematic reviews", BMJ, 372, pp.n71~ (2021)
- "Insurance Reimbursement Criteria for Liver Disease Medications"[URL]
- Whiting PF, "QUADAS-2 : a revised tool for the quality assessment of diagnostic accuracy studies", Ann Intern Med, 155, pp.529~536 (2011)
- Schneider A, "A novel statistical model for analyzing data of a systematic review generates optimal cutoff values for fractional exhaled nitric oxide for asthma diagnosis", J Clin Epidemiol, 92, pp.69~78 (2017)
- Steinhauser S, "Modelling multiple thresholds in meta-analysis of diagnostic test accuracy studies", BMC Med Res Methodol, 16, pp.97~ (2016)
- Lesmana CR, "Diagnostic accuracy of transient elastography(FibroScan)versus the aspartate transaminase to platelet ratio index in assessing liver fibrosis in chronic hepatitis B : the role in primary care setting", J Clin Pathol, 64, pp.916~920 (2011)
- Leung VY, "Quantitative elastography of liver fibrosis and spleen stiffness in chronic hepatitis B carriers : comparison of shearwave elastography and transient elastography with liver biopsy correlation", Radiology, 269, pp.910~918 (2013)
- Seo YS, "Accuracy of transient elastography in assessing liver fibrosis in chronic viral hepatitis : A multicentre, retrospective study", Liver Int, 35, pp.2246~2255 (2015)
- Huang R, "Fibroscan improves the diagnosis sensitivity of liver fibrosis in patients with chronic hepatitis B", Exp Ther Med, 11, pp.1673~1677 (2016)
- Li Y, "Development of algorithms based on serum markers and transient elastography for detecting significant fibrosis and cirrhosis in chronic hepatitis B patients : Significant reduction in liver biopsy", Hepatol Res, 46, pp.1367~1379 (2016)
- Liang XE, "Optimization of hepatitis B cirrhosis detection by stepwise application of transient elastography and routine biomarkers", J Gastroenterol Hepatol, 32, pp.459~465 (2017)
- Zhao J, "Evaluating the significance of viscoelasticity in diagnosing earlystage liver fibrosis with transient elastography", PLoS One, 12, pp.e0170073~ (2017)
- Li Q, "Diagnostic accuracy of liver stiffness measurement in chronic hepatitis B patients with normal or mildly elevated alanine transaminase levels", Sci Rep, 8, pp.5224~ (2018)
- Li S, "Systematic review with meta-analysis : Significant histological changes among treatment-naïve chronic hepatitis B patients with normal alanine aminotransferase levels by different criteria", Aliment Pharmacol Ther, 58, pp.648~658 (2023)
- Nguyen LH, "Histologic changes in liver tissue from patients with chronic hepatitis B and minimal increases in levels of alanine aminotransferase : a meta-analysis and systematic review", Clin Gastroenterol Hepatol, 12, pp.1262~1266 (2014)
- Castera L, "Noninvasive methods to assess liver disease in patients with hepatitis B or C", Gastroenterology, 142, pp.1293~1302 (2012)
- Erman A, "Estimating chronic hepatitis C prognosis using transient elastography-based liver stiffness : A systematic review and meta-analysis", J Viral Hepat, 25, pp.502~513 (2018)
- Erman A, "Estimation of fibrosis progression rates for chronic hepatitis C : a systematic review and meta-analysis update", BMJ Open, 9, pp.e027491~ (2019)
- Pavlov CS, "Systematic review with meta-analysis : diagnostic accuracy of transient elastography for staging of fibrosis in people with alcoholic liver disease", Aliment Pharmacol Ther, 43, pp.575~585 (2016)
- Castera L, "Biopsy and non-invasive methods for the diagnosis of liver fibrosis : does it take two to tango?", Gut, 59, pp.861~866 (2010)
- Tsochatzis EA, "Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C", Hepatology, 60, pp.832~843 (2014)
- Kim SU, "Variability in liver stiffness values from different intercostal spaces", Liver Int, 29, pp.760~766 (2009)
- Cho HJ, "Serum aminotransferase levels instead of etiology affects the accuracy of transient elastography in chronic viral hepatitis patients", J Gastroenterol Hepatol, 26, pp.492~500 (2011)
- Kim SU, "Factors that affect the diagnostic accuracy of liver fibrosis measurement by Fibroscan in patients with chronic hepatitis B", Aliment Pharmacol Ther, 32, pp.498~505 (2010)
- Myers RP, "Prevalence, risk factors and causes of discordance in fibrosis staging by transient elastography and liver biopsy", Liver Int, 30, pp.1471~1480 (2010)
- Wong GL, "Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients", Clin Gastroenterol Hepatol, 7, pp.227~233 (2009)
- Ji D, "Unreliable estimation of fibrosis regression during treatment by liver stiffness measurement in patients with chronic hepatitis B", Am J Gastroenterol, 116, pp.1676~1685 (2021)
- European Association for Study of Liver, "EASL-ALEH Clinical Practice Guidelines : Non-invasive tests for evaluation of liver disease severity and prognosis", J Hepatol, 63, pp.237~264 (2015)
- Rosenberger KJ, "Empirical comparisons of meta-analysis methods for diagnostic studies : a meta-epidemiological study", BMJ Open, 12, pp.e055336~ (2022)
- Mueller S, "Liver stiffness : a novel parameter for the diagnosis of liver disease", Hepat Med, 2, pp.49~67 (2010)